Back to Results

Nuo Therapeutics Inc (AURX)

Featured in Overvalued Stocks

Nuo Therapeutics, Inc. is a Houston, Texas-based biotechnology company focused on regenerative therapies in the United States. The company develops, commercializes, and markets cell-based technologies designed to support the body’s natural healing processes. Its main product, the Aurix System, separates a patient’s own blood to create a platelet-based treatment used in chronic wound care. Nuo Therapeutics serves hospital outpatient wound care clinics and private practice physicians treating chronic wounds. Founded in 1998, the company was previously known as Cytomedix, Inc. and adopted its current name in November 2014. Its common stock trades on OTC Markets under the symbol AURX.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
OTC-AURX
$0.73
-27.1% Downside
Overvalued
$3
200.0% Upside
Bargain
Fair
—
—
—
0.0%
September 2, 2026
-20.3x
-35.0x
11.7x
45.988 M
49.249 M
2.2%
41.9%
-18.3
—
71.2%
Send a message
Valuation • Fair Value

Nuo Therapeutics Inc (OTC-AURX) Fair Value by Valuation Model

Compare the primary fair value estimate for Nuo Therapeutics Inc (OTC-AURX) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$0.73

Estimated downside of 27.1% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

$0.65

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

$0.76

Earnings power value estimate.

Comps Fair Value

$0.80

Comparable-company valuation reference.

Analyst Price Target

$3

Analysts imply upside of 200.0%.

How to read these valuation models

Use this section to compare the primary fair value estimate for Nuo Therapeutics Inc (OTC-AURX) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Nuo Therapeutics Inc (OTC-AURX)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

4.131 M

Current operating scale indicator.

Revenue Forecast

5.749 M

Forward revenue estimate.

EBITDA

-2.126 M

Current operating profitability reference.

EBITDA Forecast

-1.745 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Nuo Therapeutics Inc (OTC-AURX) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Nuo Therapeutics Inc (OTC-AURX)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

4

Mid-range quality score.

Beneish M-Score

-2.59

No elevated caution signal from this screen.

Altman Z-Score

-18.3

Lower score that deserves closer risk review.

FCF / Net Income

71.2%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Nuo Therapeutics Inc (OTC-AURX). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Nuo Therapeutics Inc (OTC-AURX)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

September 2, 2026

Days to Earnings

43

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Nuo Therapeutics Inc (OTC-AURX), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Nuo Therapeutics Inc (OTC-AURX) Stock Forecast & Technical Outlook

Review Nuo Therapeutics Inc (OTC-AURX) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Nuo Therapeutics Inc (OTC-AURX) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Nuo Therapeutics Inc (OTC-AURX) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Nuo Therapeutics Inc (OTC-AURX) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Nuo Therapeutics Inc (OTC-AURX) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Nuo Therapeutics Inc (OTC-AURX) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Nuo Therapeutics Inc (OTC-AURX)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Nuo Therapeutics Inc (OTC-AURX) has a Strong Buy consensus, with 1 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 1
Hold 0
Sell 0
FAQ • Fast Investor Answers

Nuo Therapeutics Inc (OTC-AURX) Stock FAQ

Quick answers about Nuo Therapeutics Inc (OTC-AURX) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$0.73
Estimated downside 27.1%
Valuation Rating
Overvalued
Estimated downside of 27.1%
Analyst Target
$3
Implied upside 200.0%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Nuo Therapeutics Inc (OTC-AURX) is $0.73. This implies an estimated downside of 27.1% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 27.1% versus the current market price.

The available analyst price target for Nuo Therapeutics Inc (OTC-AURX) is $3. The analyst target implies estimated upside of 200.0%.

The current financial health read for Nuo Therapeutics Inc (OTC-AURX) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Nuo Therapeutics Inc (OTC-AURX) is September 2, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Nuo Therapeutics Inc (OTC-AURX) is -20.3x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Nuo Therapeutics Inc is 45.988 M.

The current enterprise value listed for Nuo Therapeutics Inc is 49.249 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Nuo Therapeutics Inc is OTC-AURX, and the stock is listed on OTC Markets.

Nuo Therapeutics Inc (OTC-AURX) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for Nuo Therapeutics Inc is 2.2%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Nuo Therapeutics Inc is 41.9%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks on OTC Markets View more

CSL Ltd (CSLLY) CSL Ltd (CSLLY)
Swedish Orphan Biovitrum AB ADR (BIOV.F) Swedish Orphan Biovitrum AB ADR (BIOV.F)
Grifols SA ADR (GIKLY) Grifols SA ADR (GIKLY)
Bavarian Nordic A/S ADR (BVNRY) Bavarian Nordic A/S ADR (BVNRY)
Mesoblast Ltd (MEOBF) Mesoblast Ltd (MEOBF)
Galapagos NV (GLPGF) Galapagos NV (GLPGF)
Pharma Mar SAU (PHMMF) Pharma Mar SAU (PHMMF)
Biogaia AB ADR (BIOGY) Biogaia AB ADR (BIOGY)
Kuros Biosciences AG (CSBTF) Kuros Biosciences AG (CSBTF)
Clinuvel Pharmaceuticals Ltd (CLVLF) Clinuvel Pharmaceuticals Ltd (CLVLF)
Northwest Biotherapeutics Inc (NWBO) Northwest Biotherapeutics Inc (NWBO)
Spectral Med Inc (EDTXF) Spectral Med Inc (EDTXF)
Cytodyn Inc (CYDY) Cytodyn Inc (CYDY)
Innate Pharma (IPHYF) Innate Pharma (IPHYF)
Vaxart Inc (VXRT) Vaxart Inc (VXRT)
CapForce Inc (CFOR) CapForce Inc (CFOR)
Adocia SA ADR (ADOCY) Adocia SA ADR (ADOCY)
Cell Source Inc (CLCS) Cell Source Inc (CLCS)
Protext Mobility Inc (TXTM) Protext Mobility Inc (TXTM)
MindMaze Therapeutics Holding SA (RLFTF) MindMaze Therapeutics Holding SA (RLFTF)
Sernova Corp (SEOVF) Sernova Corp (SEOVF)
Microbix Biosystems Inc. (MBXBF) Microbix Biosystems Inc. (MBXBF)
Resverlogix Corp. (RVXCF) Resverlogix Corp. (RVXCF)
Medicenna Therapeutics Corp (MDNAF) Medicenna Therapeutics Corp (MDNAF)